retaplase recombinant (Retavase®)
Fibrinolytic (thrombolytic)
Reteplase is a DNA recombinant human tissue-type plasminogen activator (TPA) which acts as a catalyst in the conversion of plasminogen to plasmin.
Plasmin is responsible for degrading the fibrin mesh-like blood clot.
Within minutes
half-life between 13 and 16 minutes.
Thrombolysis management of actue MI (not approved for use in ischemic stroke).
Active internal bleeding
History of CVA
Recent reuologic surgery or trauma
Bleeding disorders
Severe uncontrolled hypertension.
Caution in pregnancy
Hemorrhage
Anemia
Aspirin and heparin may increase risk of bleeding. Both are typically given concurrently to increase thrombolytic properties.
A complete administration kit contains 2 10 unit vials of medication, diluent, syringe, needle and dispensing pin.
Administer as IV bolus of 10 units injected over 2 minutes, repeat in 30 minutes.
Not recommended
Pregnancy Safety: Category C
Reconstitute with sterile water according to manufacturer's recommendations.